Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brickell Biotech and Kaken ink derma deal

This article was originally published in Scrip

Executive Summary

Miami-based Brickell Biotech is licensing its BBI-4000, a novel, topical soft-anticholinergic in development for patients with primary axillary hyperhidrosis, to Japan's Kaken Pharmaceuticals. Kaken will have the rights to develop and commercialize the drug in Japan – the world's second biggest dermatology market – and some other Asian countries. In return, the Japanese firm will pay Brickell an upfront sum and milestone payments based on certain objectives. Tiered royalties based on sales will also be paid to Brickell following launch. No further terms of the agreement have been released. BBI-4000 is an anticholinergic, which works by blocking the action of acetylcholine, a molecule that transmits the signals within the nervous system responsible for a number of functions, including activating the sweat glands. Soft-anticholinergics like BBI-4000 exert their action topically and are metabolized rapidly into a less active metabolite when they reach the blood system. It is thought this could allow effective doses to be used without the limiting systemic side-effects associated with other drugs in this class. Brickell is a clinical-stage company that focuses on developing and commercializing innovative drugs for skin diseases. Kaken is a specialty pharmaceutical company with a strong presence in dermatology and orthopedics. Its main R&D focus is on inflammation, immunology, pain and antifungals.

You may also be interested in...

Brickell’s Phase III Data Sets Up NDA Filing In Axillary Hyperhidrosis

Meeting all primary and secondary endpoints in a pair of pivotal trials, Brickell says sofpironium bromide gel will be ready for FDA filing in mid-2022. The topical is already approved in Japan as Ecclock.

Smaller EU Countries Call for More Comparative Trials

More should be done to incentivize comparative clinical trials so as to allow better decisions on drug pricing to be taken, said Austria’s representative at a recent meeting of EU health ministers.

Nordic Countries To Agree Closer Collaboration On Joint Price Negotiation and Procurement

Five Nordic countries are agreeing a common strategy for closer collaboration on access to hospital drugs.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts